Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hemorrhagic Fever, Ebola | 3 | 2018 | 1475 | 0.46 | Why? |
| Epidemics | 3 | 2018 | 6407 | 0.24 | Why? |
| Biomedical Research | 2 | 2018 | 5270 | 0.20 | Why? |
| Africa, Western | 2 | 2018 | 363 | 0.19 | Why? |
| Monkeypox virus | 1 | 2018 | 43 | 0.19 | Why? |
| Monkeypox | 1 | 2018 | 40 | 0.18 | Why? |
| Interferon beta-1b | 1 | 2020 | 274 | 0.18 | Why? |
| Clinical Protocols | 4 | 2021 | 2734 | 0.17 | Why? |
| Clinical Deterioration | 1 | 2021 | 473 | 0.16 | Why? |
| Immunity, Mucosal | 1 | 2019 | 426 | 0.15 | Why? |
| Caliciviridae Infections | 1 | 2019 | 229 | 0.15 | Why? |
| United Kingdom | 12 | 2021 | 18046 | 0.15 | Why? |
| Norovirus | 1 | 2019 | 294 | 0.15 | Why? |
| Fomites | 1 | 2021 | 709 | 0.14 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.14 | Why? |
| Ribavirin | 1 | 2020 | 1182 | 0.13 | Why? |
| RNA, Small Interfering | 1 | 2018 | 817 | 0.13 | Why? |
| Hospital Mortality | 6 | 2021 | 22087 | 0.12 | Why? |
| Hospitals | 3 | 2021 | 11793 | 0.12 | Why? |
| Nasal Mucosa | 1 | 2019 | 1218 | 0.11 | Why? |
| Asthma | 2 | 2021 | 4383 | 0.11 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.11 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.09 | Why? |
| Cross Infection | 2 | 2021 | 8675 | 0.09 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.09 | Why? |
| World Health Organization | 4 | 2021 | 4213 | 0.09 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.08 | Why? |
| Sierra Leone | 2 | 2018 | 267 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Adrenal Cortex Hormones | 2 | 2020 | 6537 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.08 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.07 | Why? |
| Communicable Diseases, Emerging | 1 | 2018 | 2523 | 0.07 | Why? |
| Mortality | 2 | 2019 | 7132 | 0.07 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3832 | 0.06 | Why? |
| Zika Virus Infection | 1 | 2017 | 1920 | 0.06 | Why? |
| Patient Care Team | 1 | 2017 | 3556 | 0.06 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.06 | Why? |
| Prospective Studies | 6 | 2021 | 43301 | 0.06 | Why? |
| Health Policy | 1 | 2021 | 6242 | 0.05 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.05 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.05 | Why? |
| Humans | 23 | 2021 | 930598 | 0.05 | Why? |
| Surface Properties | 1 | 2021 | 448 | 0.05 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.05 | Why? |
| Travel | 1 | 2018 | 7220 | 0.05 | Why? |
| Poxviridae Infections | 1 | 2018 | 31 | 0.05 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.05 | Why? |
| Sequence Analysis | 1 | 2020 | 496 | 0.05 | Why? |
| DNA, Complementary | 1 | 2020 | 568 | 0.05 | Why? |
| Influenza, Human | 2 | 2021 | 10779 | 0.04 | Why? |
| Teratogens | 1 | 2017 | 15 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.04 | Why? |
| Microbial Viability | 1 | 2021 | 406 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 243 | 0.04 | Why? |
| Microcephaly | 1 | 2017 | 181 | 0.04 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.04 | Why? |
| Female | 12 | 2021 | 380317 | 0.04 | Why? |
| Respiration, Artificial | 4 | 2021 | 22116 | 0.04 | Why? |
| Molecular Epidemiology | 1 | 2020 | 1638 | 0.03 | Why? |
| Proto-Oncogene Proteins | 1 | 2017 | 340 | 0.03 | Why? |
| Male | 11 | 2021 | 367725 | 0.03 | Why? |
| London | 1 | 2021 | 2166 | 0.03 | Why? |
| Environmental Microbiology | 1 | 2019 | 575 | 0.03 | Why? |
| Disease Outbreaks | 2 | 2019 | 27595 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2021 | 1061 | 0.03 | Why? |
| Critical Care | 3 | 2021 | 14081 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 1439 | 0.03 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.03 | Why? |
| Aged | 7 | 2021 | 215776 | 0.03 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.03 | Why? |
| Interferon-alpha | 1 | 2019 | 1442 | 0.03 | Why? |
| Nigeria | 1 | 2018 | 2292 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.03 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 11367 | 0.03 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.03 | Why? |
| Informed Consent | 1 | 2018 | 890 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Antibodies | 1 | 2017 | 846 | 0.03 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.03 | Why? |
| DNA, Viral | 1 | 2020 | 2521 | 0.03 | Why? |
| Medical Staff, Hospital | 1 | 2020 | 1258 | 0.03 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.02 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2021 | 3444 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3633 | 0.02 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.02 | Why? |
| Adult | 6 | 2021 | 244371 | 0.02 | Why? |
| England | 1 | 2020 | 5116 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.02 | Why? |
| Infant | 2 | 2020 | 30274 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.02 | Why? |
| Placenta | 1 | 2017 | 1531 | 0.02 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 2984 | 0.02 | Why? |
| Transcriptome | 1 | 2019 | 3466 | 0.02 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2019 | 3629 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Disaster Planning | 1 | 2017 | 1680 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2017 | 3614 | 0.02 | Why? |
| Influenza Vaccines | 1 | 2019 | 2941 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.02 | Why? |
| Nervous System Diseases | 1 | 2021 | 4092 | 0.01 | Why? |
| Length of Stay | 1 | 2019 | 11042 | 0.01 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.01 | Why? |
| Child | 2 | 2020 | 70012 | 0.01 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.01 | Why? |
| Contact Tracing | 1 | 2018 | 8448 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2021 | 11497 | 0.01 | Why? |
| Virus Replication | 1 | 2017 | 14331 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
| Public Health | 1 | 2018 | 16359 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |
Dunning's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(135)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(255)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_